Business
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
CAMBRIDGE, Mass., May 15, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a comprehensive business update.
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/c9263ba237096432d6eecb503d00c621"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EnXUQuraDaU8YuQc73hrYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/c9263ba237096432d6eecb503d00c621","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ieBjz_WHKzoBhWvcgJylgw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/c9263ba237096432d6eecb503d00c621","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/KMif5s_.AdKs2HOlkfsv9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/c9263ba237096432d6eecb503d00c621","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Product Development Highlights: ","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial ","length":129,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reported additional preclinical data for EB-003 demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects ","length":187,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":316,"olType":false},{"type":"text","content":"Corporate and Business Development Highlights:","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Strengthened intellectual property portfolio with new patent issuances and allowances across EVM301 and EVM401 series","length":117,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced the withdrawal by AbbVie, Inc. of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276, which appears relevant to the bretisilocin molecule (GM-2505) acquired by AbbVie, Inc.","length":255,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presented at and Participated in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation F...